IP Library › Granted Patent US 12,415,859
Granted Patent B2
US 12,415,859 · App. 16/717,189 · Granted Sep 16, 2025

Methods of producing heterodimeric antibodies

Inventors: Pedro Jose Alfonso Martin (Wayne, PA); Michael Capaldi (Chalfont, PA); Jeffrey Cohen (Kennett Square, PA); Andrew Detzel (Media, PA); Joseph Sakyiama (Lower Gwynedd, PA)
Assignee: GENMAB A/S
C07K16/2863C07K16/2809C07K16/2866C07K16/2878C07K2317/10C07K2317/31C07K2317/526C07K2317/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,859
App. No.
16/717,189
Granted
Sep 16, 2025
Kind
B2
Abstract

The invention relates to methods of producing heterodimeric antibodies.

Claims (46)

1. A method of producing a heterodimeric antibody, comprising

a) providing a first homodimeric antibody comprising a first Fc region of an immunoglobulin comprising a first CH3 region and a second homodimeric antibody comprising a second Fc region of an immunoglobulin comprising a second CH3 region, wherein the amino acid sequences of the first CH3 region and the second CH3 regions are different and are such that the heterodimeric interaction between the first CH3 region and the second CH3 region is stronger than a homodimeric interaction between the first CH3 region or a homodimeric interaction between the second CH3 region;

b) combining the first homodimeric antibody and the second homodimeric antibody into a mixture;

c) incubating the mixture in the presence of a reducing agent;

d) removing the reducing agent to produce the heterodimeric antibody, and

e) controlling percentage saturation of dissolved oxygen (% DO 2 ) to be 15% or less in step d), wherein 15% DO 2 is equivalent to 1.44 mg/L or 45 μM DO 2 .

2. The method of claim 1 , wherein the % DO 2 in the mixture in step d) is about 10% or less, about 9% or less, about 8% or less, about 7% or less, about 6% or less, about 5% or less, about 4% or less, about 3% or less, about 2% or less or about 1% or less.

3. The method of claim 2 , wherein % DO 2 is controlled by an overlay of nitrogen.

4. The method of claim 3 , wherein the first homodimeric antibody and the second homodimeric antibody are combined into the mixture in step b) at a molar ratio of between about 1:1 to about 1:2.

5. The method of claim 3 , wherein the first homodimeric antibody and the second homodimeric antibody are combined into the mixture in step b) at the molar ratio of about 1.05:1.

6. The method of claim 1 , wherein total concentration of immunoglobulin in the mixture is about 10.5 g/L.

7. The method of claim 6 , wherein the mixture is incubated in the presence of the reducing agent for about 10 minutes or longer.

8. The method of claim 7 , wherein the mixture is incubated in the presence of the reducing agent from about 10 minutes to about 24 hours.

9. The method of claim 7 , wherein the reducing agent is 2-mercaptoethylamine (2-MEA), a chemical derivative of 2-MEA, L-cysteine or D-cysteine.

10. The method of claim 9 , wherein concentration of 2-MEA in the mixture is about 35 mM.

11. The method of claim 9 , wherein the mixture comprises a buffer.

12. The method of claim 11 , wherein the buffer comprises a sodium acetate buffer.

13. The method of claim 12 , wherein the buffer further comprises NaCl.

14. The method of claim 13 , wherein the buffer comprises about 100 mM sodium acetate and about 30 mM NaCl.

15. The method of claim 14 , wherein the pH of the buffer is about 7.3.

16. The method of claim 1 , wherein the reducing agent is removed by filtration.

17. The method of claim 16 , wherein the filtration is diafiltration.

18. The method of claim 1 , wherein the first homodimeric antibody and the second homodimeric antibody are an IgG1, IgG2 or IgG4 isotype.

19. The method of claim 18 , wherein the first CH3 domain and the second CH3 domain comprise following mutations when compared to the wild-type IgG1 of SEQ ID NO: 1, wild-type IgG2 of SEQ ID NO: 2 or wild-type IgG4 of SEQ ID NO: 3: F405L/K409R, wild-type/F405L_R409K, T350I_K370T_F405L/K409R, K370W/K409R, D399AFGHILMNRSTVWY/K409R, T366ADEFGHILMQVY/K409R, L368ADEGHNRSTVQ/K409AGRH, D399FHKRQ/K409AGRH, F405IKLSTVW/K409AGRH, Y407LWQ/K409AGRH, T366Y/F405A, T366W/F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S, T366W/T366S_L368A_Y407V, L351Y_F405A_Y407V/T394W, T366I_K392M_T394W/F405A_Y407V, T366L_K392M_T394W/F405A_Y407V, L351Y_Y407A/T366A_K409F, L351Y_Y407A/T366V_K409F, Y407A/T366A_K409F, T350V_L351Y_F405A_Y407V/T350V_T366L_K392L_T394W, K409D/D399K, K409E/D399R, K409D_K360D/D399K_E356K, K409D_K360D/D399E_E356K, K409D_K370D/D399K_E357K, K409D_K370D/D399E_E357K, K409D_K392D/D399K_E356K_E357K or K409D_K392D/D399E_E356K_E357K, wherein the amino acid positions are numbered according to the EU Index.

20. The method of claim 19 , wherein the first Fc region and/or the second Fc region comprise one or more mutations when compared to the wild-type IgG1 of SEQ ID NO: 1, wild-type IgG2 of SEQ ID NO: 2 or wild-type IgG4 of SEQ ID NO: 3 that modulate binding of the first Fc region and/or the second Fc region to an Fcγ receptor (FcγR), an FcRn, or to protein A.

21. The method of claim 20 , wherein the FcγR is FcγRI, FcγRIIa, FcγRIIb or FcγRIII.

22. The method of claim 20 , wherein the one or more mutations that modulate binding of the first Fc region and/or the second Fc region to the Fcγ receptor are L234A_L235A, F234A_L235A, S228P_F234A_L235A, S228P_L234A_L235A, V234A_G237A_P238S_H268A_V309L_A330S_P331S, V234A_G237A, H268Q_V309L_A330S_P331S, S267E_L328F, L234F_L235E_D265A, L234A_L235A_G237A_P238S_H268A_A330S_P331S or S228P_F234A_L235A_G237A_P238S, wherein the amino acid positions are numbered according to the EU Index.

23. The method of claim 20 , wherein the one or more mutations that modulate binding of the first Fc region and/or the second Fc region to the FcRn are M428L_N434S, M252Y_S254T_T256E, T250Q_M428L, N434A_T307A_E380A_N434A, H435A, P257I_N434H, D376V_N434H, M252Y_S254T_T256E_H433K_N434F, T308P_N434A or H435R, wherein the amino acid positions are numbered according to the EU Index.

24. The method of claim 20 , wherein the one or more mutations that modulate binding of the first Fc region and/or the second Fc region to protein A are Q311R, Q311K, T307P_L309Q, T307P_V309Q, T307P_L309Q_Q311R, T307P_V309Q_Q311R, H435R or H435R_Y436F, wherein the amino acid positions are numbered according to the EU Index.

25. The method of claim 1 , wherein the steps of producing the heterodimeric antibody are conducted under GMP-compliant conditions.

26. The method of claim 25 , wherein the steps of producing the heterodimeric antibody are conducted during manufacture of a drug substance comprising the heterodimeric antibody.

27. The method of claim 1 , wherein the heterodimeric antibody is a bispecific antibody.

28. The method of claim 27 , wherein the bispecific antibody binds CD3, CD123, BCMA, EGFR or c-Met, or any combination thereof.

29. The method of claim 1 , wherein a mass ratio of the reducing agent to total immunoglobulin in the mixture is between about 1.0 and about 5.0.

30. The method of claim 29 , wherein the mass ratio is between about 1.4 and about 3.8.

31. The method of claim 29 , wherein the mass ratio is between about 3.3 and about 4.4.

32. The method of claim 1 , wherein the % DO 2 in the mixture is about 10% or less in step d).

33. The method of claim 1 , wherein the % DO 2 in the mixture is about 5% or less in step d).

34. A method of producing a heterodimeric antibody, comprising

a) providing a first homodimeric antibody comprising a first Fc region of an immunoglobulin comprising a first CH3 region and a second homodimeric antibody comprising a second Fc region of an immunoglobulin comprising a second CH3 region, wherein the amino acid sequences of the first CH3 region and the second CH3 regions are different and are such that the heterodimeric interaction between the first CH3 region and the second CH3 region is stronger than a homodimeric interaction between the first CH3 region or a homodimeric interaction between the second CH3 region;

b) combining the first homodimeric antibody and the second homodimeric antibody into a mixture;

c) incubating the mixture in the presence of a reducing agent;

d) removing the reducing agent to produce the heterodimeric antibody, and

e) controlling the concentration of oxygen to be 0.480 mg/L or less, or 14.99 μM or less, in step d).

35. The method of claim 1 , wherein the % DO 2 in the mixture in step d) is about 4% or less.

36. The method of claim 1 , wherein the % DO 2 in the mixture in step d) is about 3% or less.

Assignments (4)
SECURITY INTEREST Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073949/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2020
From: ALFONSO MARTIN, PEDRO JOSE; CAPALDI, MICHAEL T.; COHEN, JEFFREY; DETZEL, ANDREW; SAKYIAMA, JOSEPH
To: JANSSEN BIOTECH, INC.
Reel/Frame 054029/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: JANSSEN BIOTECH, INC.
To: GENMAB A/S
Reel/Frame 054001/0013 →
Continuity (2)
Provisional Application 62781180 · Dec 18, 2018
Related Publication 20200190200A1 · Jun 18, 2020
References Cited (245)
US 2592668A · Dufour · 1952 [cited by applicant]
US 5292668A · Paulus · 1994 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5807706A · Carter et al. · 1998 [cited by applicant]
US 6528286B1 · Ryll · 2003 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6822075B2 · Bjorck et al. · 2004 [cited by applicant]
US 7537930B2 · Goldenberg et al. · 2009 [cited by applicant]
US 7723485B2 · Junutula et al. · 2010 [cited by applicant]
US 7960512B2 · Stavenhagen et al. · 2011 [cited by applicant]
US 8236931B2 · De Wildt et al. · 2012 [cited by applicant]
US 8586713B2 · Davis et al. · 2013 [cited by applicant]
US 8911726B2 · Takahashi et al. · 2014 [cited by applicant]
US 9062120B2 · Hunter et al. · 2015 [cited by applicant]
US 9150663B2 · Abrijn et al. · 2015 [cited by applicant]
US 9212230B2 · Schuurman et al. · 2015 [cited by applicant]
US 9540433B2 · Verploegen et al. · 2017 [cited by applicant]
US 9580508B2 · Chiu et al. · 2017 [cited by applicant]
US 9593164B2 · Chiu et al. · 2017 [cited by applicant]
US 9595164B2 · Robbins et al. · 2017 [cited by applicant]
US 9695242B2 · Chiu et al. · 2017 [cited by applicant]
US 9850310B2 · Gaudet et al. · 2017 [cited by applicant]
US 9896513B2 · Krogh et al. · 2018 [cited by applicant]
US 9955369B2 · Chen et al. · 2018 [cited by applicant]
US 10239952B2 · Scheinberg et al. · 2019 [cited by applicant]
US 10344050B2 · Gramer et al. · 2019 [cited by applicant]
US 10590206B2 · Labrijn et al. · 2020 [cited by applicant]
US 10597464B2 · Labrijn et al. · 2020 [cited by applicant]
US 10759867B2 · Parren et al. · 2020 [cited by applicant]
US 10865253B2 · Labrijn et al. · 2020 [cited by applicant]
US 10906991B2 · Schuurman et al. · 2021 [cited by applicant]
US 11180572B2 · De Jong et al. · 2021 [cited by applicant]
US 11485796B2 · Labrijn et al. · 2022 [cited by applicant]
US 11492371B2 · Gramer · 2022 [cited by examiner]
US 11866514B2 · Labrijn et al. · 2024 [cited by applicant]
US 12049512B2 · Parren et al. · 2024 [cited by applicant]
US 12173076B2 · Beurskens et al. · 2024 [cited by applicant]
US 12247065B2 · Hibbert et al. · 2025 [cited by applicant]
US 20040038894A1 · Daeron et al. · 2004 [cited by applicant]
US 20050037000A1 · Stavenhagen et al. · 2005 [cited by applicant]
US 20050208519A1 · Liew et al. · 2005 [cited by applicant]
US 20060074225A1 · Chamberlain et al. · 2006 [cited by applicant]
US 20060134105A1 · Lazar et al. · 2006 [cited by applicant]
US 20060194280A1 · Dillon et al. · 2006 [cited by applicant]
US 20070287170A1 · Davis et al. · 2007 [cited by applicant]
US 20080051469A1 · Brahmbhatt et al. · 2008 [cited by applicant]
US 20090042253A1 · Hiller · 2009 [cited by applicant]
US 20090182127A1 · Kjaergaard et al. · 2009 [cited by applicant]
US 20090202546A1 · Harris et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20100028637A1 · Tavsanli et al. · 2010 [cited by applicant]
US 20100105874A1 · Schuurman et al. · 2010 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20110123532A1 · Gurney et al. · 2011 [cited by applicant]
US 20120149876A1 · Von Kreudenstein et al. · 2012 [cited by applicant]
US 20130039913A1 · Labrijn et al. · 2013 [cited by applicant]
US 20130177555A1 · Wilkinson et al. · 2013 [cited by applicant]
US 20130195849A1 · Spreter Von Kreudenstein et al. · 2013 [cited by applicant]
US 20140141000A1 · Chiu et al. · 2014 [cited by applicant]
US 20140170148A1 · De Goeij et al. · 2014 [cited by applicant]
US 20140170149A1 · Neijssen et al. · 2014 [cited by applicant]
US 20140242075A1 · Parren et al. · 2014 [cited by applicant]
US 20140273092A1 · Flikweert et al. · 2014 [cited by applicant]
US 20140303356A1 · Gramer et al. · 2014 [cited by applicant]
US 20150175692A1 · Di Padova · 2015 [cited by examiner]
US 20150175707A1 · De Jong et al. · 2015 [cited by applicant]
US 20150337049A1 · Labrijn et al. · 2015 [cited by applicant]
US 20150353636A1 · Parren et al. · 2015 [cited by applicant]
US 20160046727A1 · Labrijn et al. · 2016 [cited by applicant]
US 20160159930A1 · Schuurman et al. · 2016 [cited by applicant]
US 20170233497A1 · Labrijn et al. · 2017 [cited by applicant]
US 20170327597A1 · Labrijn et al. · 2017 [cited by applicant]
US 20170369590A1 · De Goeij et al. · 2017 [cited by applicant]
US 20180118849A1 · Klein et al. · 2018 [cited by applicant]
US 20180201693A1 · Hibbert et al. · 2018 [cited by applicant]
US 20190352423A1 · De Goeij et al. · 2019 [cited by applicant]
US 20200048304A1 · Gramer et al. · 2020 [cited by applicant]
US 20200181277A1 · Beurskens et al. · 2020 [cited by applicant]
US 20200262932A1 · Labrijn et al. · 2020 [cited by applicant]
US 20200332022A1 · Labrijn et al. · 2020 [cited by applicant]
US 20210107988A1 · Oostindie et al. · 2021 [cited by applicant]
US 20210163619A1 · Parren et al. · 2021 [cited by applicant]
US 20210230301A1 · De Jong et al. · 2021 [cited by applicant]
US 20210269509A1 · Hibbert et al. · 2021 [cited by applicant]
US 20230227495A1 · Gramer et al. · 2023 [cited by applicant]
US 20230322947A1 · Labrijn et al. · 2023 [cited by applicant]
US 20240209117A1 · Labrijn et al. · 2024 [cited by applicant]
US 20250043018A1 · Parren et al. · 2025 [cited by applicant]
AU 2017261467A1 · 2017 [cited by applicant]
DE 19859115A1 · 2000 [cited by applicant]
EP 1693386A1 · 2006 [cited by applicant]
EP 1870459A1 · 2007 [cited by applicant]
JP 2015143238A · 2015 [cited by applicant]
WO 198801649A1 · 1988 [cited by applicant]
WO 199201047A1 · 1992 [cited by applicant]
WO 199413804A1 · 1994 [cited by applicant]
WO 9627011A1 · 1996 [cited by applicant]
WO 9804592A1 · 1998 [cited by applicant]
WO 199844001A1 · 1998 [cited by applicant]
WO 9850431A2 · 1998 [cited by applicant]
WO 9955369A1 · 1999 [cited by applicant]
WO 02100348A2 · 2002 [cited by applicant]
WO 2004035607A2 · 2004 [cited by applicant]
WO 2005000899A2 · 2005 [cited by applicant]
WO 2005062916A2 · 2005 [cited by applicant]
WO 2006047340A2 · 2006 [cited by applicant]
WO 2006106905A1 · 2006 [cited by applicant]
WO 2007059782A1 · 2007 [cited by applicant]
WO 2007103112A2 · 2007 [cited by applicant]
WO 2007110205A2 · 2007 [cited by applicant]
WO 2007147901A1 · 2007 [cited by applicant]
WO 2008052933A2 · 2008 [cited by applicant]
WO 2008119353A1 · 2008 [cited by applicant]
WO 2008145140A2 · 2008 [cited by applicant]
WO 2008145142A1 · 2008 [cited by applicant]
WO 2009009407A1 · 2009 [cited by applicant]
WO 2009080251A1 · 2009 [cited by applicant]
WO 2009085462A1 · 2009 [cited by applicant]
WO 2009089004A1 · 2009 [cited by applicant]
WO 2010001251A2 · 2010 [cited by applicant]
WO 2010063785A2 · 2010 [cited by applicant]
WO 2010129304A2 · 2010 [cited by applicant]
WO 2010151792A1 · 2010 [cited by applicant]
WO 2011131746A2 · 2011 [cited by applicant]
WO 2011133886A2 · 2011 [cited by applicant]
WO 2011143545A1 · 2011 [cited by applicant]
WO 2012058768A1 · 2012 [cited by applicant]
WO 2012116453A1 · 2012 [cited by applicant]
WO 2012143524A2 · 2012 [cited by applicant]
WO 2013060867A2 · 2013 [cited by applicant]
WO 2013088259A2 · 2013 [cited by applicant]
WO 2013096291A2 · 2013 [cited by applicant]
WO 2013136186A2 · 2013 [cited by applicant]
WO 2013157954A1 · 2013 [cited by applicant]
WO 2016097300A1 · 2016 [cited by applicant]
WO 2017005649A1 · 2017 [cited by applicant]
Samuelson et al, Disulfide bonded protein production in [cited by examiner]
Parren, Paul, “UniBody, a novel nonactivating antibody format,” Beyond Antibodies, slideshow, 35 pages (2009). [cited by applicant]
Rispens, Theo et al., “Human IgG4 Binds to IgG4 and Conformationally Altered IgG1 via Fc-Fc Interactions,” The Journal of Immunology, vol. 182:4275-4281 (2009). [cited by applicant]
Rispens, Theo, “IgG4: an odd antibody, Fc interactions and the relation to half-molecule exchange,” Sanquin, slideshow, 42 pages (2009). [cited by applicant]
Robinson et al., “Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro,” Br. J. Cancer, vol. 99:1415-1425 (2008). [cited by applicant]
Rudikoff, S. et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci USA, vol. 79:1979-1983 (1982). [cited by applicant]
Santora, L.C. et al., “Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing,” Analytical Biochemistry, vol. 275: 98-108 (19… [cited by applicant]
Schuurman, J. et al., “Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites,” Immunology, vol. 97:693-698 (1999). [cited by applicant]
Schuurman, Janine et al., “Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange,” World BioPharm Forum, Poster, 1 page (2009). [cited by applicant]
Schuurman, Janine et al., “The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide ponds,” Molecular Immunology, vol. 38:1-8 (2001). [cited by applicant]
Schuurman, Janine, “IgG4 Fab-arm exchange,” World BioPharm Forum, slideshow, 26 pages (2009). [cited by applicant]
Schuurman, Janine, “Post-Transcriptional Modifications,” Genmab, slideshow, 43 pages (2008). [cited by applicant]
Schuurman, Janine, “The impact of Fab-arm exchange on the development of antibody therapeutics, ” Antibody Discovery & Development Forum, slideshow, 30 pages (2011). [cited by applicant]
Schuurman, Janine, “The impact of Fab-arm exchange on the development of antibody therapeutics,” Antibody Engineering and Design, slideshow, 29 pages (2011). [cited by applicant]
Schuurman, Janine, “The impact of Fab-arm exchange on the development of antibody therapeutics,” Genmab, slideshow, 30 pages (2010). [cited by applicant]
Scinicariello, F. et al., “Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions,” Immunol., vol. 111:66-74 (2004). [cited by applicant]
Shatz, W et al., “An efficient route to bispecific antibody production using single-reactor mammalian co-culture,” mAbs, vol. 8(8):1487-1497 (2016). [cited by applicant]
Skolnick, J. et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends Biotechnol., vol. 18(1):34-39) (2000). [cited by applicant]
Stubenrauch, Kay et al., “Impact of Molecular Processing in the Hinge Region of Therapeutic IgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys,” Drug Metabolism and Disposition, vol. 38(1):84-91 (2010). [cited by applicant]
Tao, M. et al. “Structural Features of Human Immunoglobulin G that Determine Isotype-specific Differences in Complement Activation,” Journal of Experimental Medicine, vol. 178:661-667 (1993). [cited by applicant]
Vajdos, F. et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis,” J Mol Biol., vol. 320(2):415-428 (2002). [cited by applicant]
Van Berkel, Patrick H.C., “Development of a production process for DuoBody: a novel human bispecific platform,” Informa/IBC Life Sciences' Bioproduction Conference, Poster, 1 page (2011). [cited by applicant]
Van De Winkel, Jan et al., “Better Antibodies by Design, 2011 R&D Day,” slideshow, 109 pages (2011). [cited by applicant]
Van Der Neut Kolfschoten, Marijn et al., “Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange,” Science, vol. 317:1554-1557 (2007). [cited by applicant]
Van Der Zee, J.S. et al., “Inhibition of complement activation by IgG4 antibodies,” Clin. exp. Immunol., vol. 64:415-422 (1986). [cited by applicant]
Van Der Zee, Jaring S. et al., “Serologic Aspects of lgG4 Antibodies. II. IgG4 Antibodies Form Small, Nonprecipitating Immune Complexes Due to Functional Monovalency,” The Journal of Immunology, vol. 137(11):3566-3571 (… [cited by applicant]
Wu, H. et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J Mol Biol., vol. 294: 151-162 (1999). [cited by applicant]
Yu, L. et al., “Interaction between bevacizumab and murine VEGF-A: a reassessment,” Investigative Ophthalmology & Visual Science, vol. 49(2): 522-527 (2008). [cited by applicant]
Zuckier et al., “Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life,” Cancer Research, 58:3905-3908 (1998). [cited by applicant]
Baert, F. et al., “Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease,” N Engl J Med., vol. 348:601-608 (2003). [cited by applicant]
Chothia, C. et al., “Canonical structures for the hypervariable regions of immunoglobulins,” J Mol Biol., vol. 196: 901-917 (1987). [cited by applicant]
Gramer, M. et al., “Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches,” MAbs, vol. 5:962-973 (2013). [cited by applicant]
Honegger, A. et al., “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol., vol. 309:657-670 (2001). [cited by applicant]
Knappik, A. et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,” J Mol Biol., vol. 296:57-86 (2000). [cited by applicant]
Lefranc, M-P. et al., “IMGT, the international ImMunoGeneTics database,” Dev Comp Immunol., vol. 27: 55-77 (2003). [cited by applicant]
Martin, A. et al., “Structural families in loops of homologous proteins: automatic classification, modeling and application to antibodies,” J Mol Biol., vol. 263: 800-815 (1996). [cited by applicant]
Stickler, M. et al., “The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site,” Genes and Immunity, vo… [cited by applicant]
Wu, T. et al., “An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity,” J Exp Med., vol. 132: 211-250 (1970). [cited by applicant]
Shi, L. et al., “De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins,” J Mol Biol., vol. 397:385-396 (2010). [cited by applicant]
U.S. Appl. No. 15/742,803, filed Jan. 8, 2018, Richard G. Hibbert. [cited by applicant]
U.S. Appl. No. 15/536,143, filed Jun. 15, 2017, Aran F. Labrijn. [cited by applicant]
U.S. Appl. No. 14/353,962, filed Apr. 24, 2014, Michael Gramer. [cited by applicant]
U.S. Appl. No. 16/426,647, filed May 30, 2019, Michael Gramer. [cited by applicant]
U.S. Appl. No. 16/777,053, filed Jan. 30, 2020, Aran Frank Labrijn. [cited by applicant]
U.S. Appl. No. 15/414,122, filed Jan. 24, 2017, Aran Frank Labrijn. [cited by applicant]
U.S. Appl. No. 14/830,336, filed Aug. 19, 2015, Aran Frank Labrijn. [cited by applicant]
U.S. Appl. No. 13/642,253, filed Oct. 24, 2012, Aran Frank Labrijn. [cited by applicant]
U.S. Appl. No. 14/934,956, filed Nov. 6, 2015, Janine Schuurman. [cited by applicant]
U.S. Appl. No. 12/593,759, filed Jan. 6, 2010, Janine Schuurman. [cited by applicant]
U.S. Appl. No. 16/921,154, filed Jul. 6, 2020, Paul Parren. [cited by applicant]
U.S. Appl. No. 14/130,543, filed May 5, 2014, Paul Parren. [cited by applicant]
U.S. Appl. No. 14/413,178, filed Mar. 17, 2015, Rob N. De Jong. [cited by applicant]
U.S. Appl. No. 17/012,102, filed Sep. 4, 2020, Rob N. De Jong. [cited by applicant]
U.S. Appl. No. 16/783,720, filed Feb. 6, 2020, Aran Frank Labrijn. [cited by applicant]
U.S. Appl. No. 14/760,157, filed Jul. 9, 2015, Aran Frank Labrijn. [cited by applicant]
U.S. Appl. No. 16/482,747, filed Aug. 1, 2019, Frank Beurskens. [cited by applicant]
U.S. Appl. No. 16/963,701, filed Jul. 21, 2020, Simone Oostindie. [cited by applicant]
U.S. Appl. No. 17/253,286, filed Dec. 17, 2020, Richard Hibbert. [cited by applicant]
Aalberse, Rob C. et al., “IgG4 breaking the rules,” Immunology, vol. 105:9-19 (2002). [cited by applicant]
Aalberse, Rob C. et al., “Serologic Aspects of lgG4 Antibodies. I. Prolonged Immunization Results in an IgG4-Restricted Response,” The Journal of Immunology, vol. 130(2):722-726 (1983). [cited by applicant]
Aalberse, Rob C. et al., “The Apparent Monovalency of Human IgG4 Is Due to Bispecificity,” Int. Arch. Allergy Immunol., vol. 118:187-189 (1999). [cited by applicant]
Aalberse, Rob C., “Physiological Fab arm exchange of IgG4 generates an anti-inflammatory antibody,” Genmab, European Antibody Congress, 36 pages (2008). [cited by applicant]
Angal, S. et al., “A Single Amino Acid Substitution Abolishes the Hetergeneity of Chimeric Mouse/Human (IgG4) Antibody,” Molecular Immunology, vol. 30(1):105-108 (1993). [cited by applicant]
Bloom, James W. et al., “Intrachain disulfide bond in the core hinge region of human IgG4,” Protein Science, vol. 6:407-415 (1997). [cited by applicant]
Bork, P., “Powers and pitfalls in sequence analysis: the 70% hurdle,” Genonne Research, vol. 10:398-400 (2000). [cited by applicant]
Brown, M. et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?,” J Immunol., vol. 156(9):3285-3291 (1996). [cited by applicant]
Brusco et al., “Molecular characterization of immunoglobulin G4 gene isoallotypes,” Eur J Immnogene, 25:349-355 (1998). [cited by applicant]
Burgess, W. et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a si… [cited by applicant]
Carlring, Jennifer et al., “A Novel Redox Method for Rapid Production of Functional Bi-Specific Antibodies For Use in Early Pilot Studies,” PLoS One, vol. 6(7):e22533, pp. 1-6 (2011). [cited by applicant]
Chames, P. et al., “Bispecific Antibodies for Cancer Therapy” Curr. Opin Drug Discvo. Devel, vol. 12(2):276-283 (2009). [cited by applicant]
Ciccimarra, F. et al., “Localization of the IgG effector site for monocyte receptors,” PNAS, 72:2081-2083(1975). [cited by applicant]
Dall'Acqua, William et al., “Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers,” Biochemistry, vol. 37:9266-9273 (1998). [cited by applicant]
Deng, Liang et al., “Detection and quantification of the human IgG4 half-molecule, HL, from unpurified cell-culture supernatants,” Biotechnol. Appl. Biochem., vol. 40:261-269 (2004). [cited by applicant]
Dick, L. et al., “C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes,” Biotechnology and Bioengineering, vol. 100(6): 1132-1143 (2008). [cited by applicant]
Genmab, “Better Antibodies by Design,” www.genmab.com, 2 pages (2011). [cited by applicant]
Genmab, “Building for a Commercial Future: Research, Development and Business Update,” slideshow, 65 pages (2006). [cited by applicant]
Genmab, “DuoBody platform, Genmab's proprietary bispecific antibody platform,” slideshow, 15 pages, (2011). [cited by applicant]
Genmab, “DuoBody, The next generation of therapeutic antibodies,” www.genmab.com, 2 pages (2011). [cited by applicant]
Genmab, “DuoBody: Innovative Bispecific Antibody Platform,” Poster for R&D Day, 1 page (2011). [cited by applicant]
Genmab, “Genmab, Beter Antibodies by Design,” slideshow, 2 pages (2011). [cited by applicant]
Genmab, “The physiological generation of bispecific IgG4 antibodies,” Sanquin Spring Symposium, slideshow, 54 pages (2007). [cited by applicant]
Genmab, “Therapeutic IgG4 antibodies engage in Fab-arm exchange with patients' IgG4 in vivo,” Antibodies as Drugs, Poster #214, 14 pages (2009). [cited by applicant]
Gunasekaran, K. et al., “Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG,” Journal of Biological Chemistry, vol. 285 (25):19637… [cited by applicant]
Hay, M. et al., “Clinical development success rates for investigational drugs,” Nature Biotechnology, vol. 32(1): 40-51 (2014). [cited by applicant]
International Preliminary Report on Patentability, PCT/EP2012/071294, dated Apr. 29, 2014, pp. 1-13. [cited by applicant]
International Preliminary Report on Patentability, PCT/IB2019/060969, dated Jun. 16, 2021, 9 pages. [cited by applicant]
International Preliminary Report on Patentabilty, PCT/EP2015/080509, dated Jun. 20, 2017, 9 pages. [cited by applicant]
International Search Report and Written Opinion, PCT/EP2012/071294, dated Apr. 26, 2013, pp. 1-20. [cited by applicant]
International Search Report and Written Opinion, PCT/EP2015/080509, dated Mar. 30, 2016, 13 pages. [cited by applicant]
International Search Report and Written Opinion, PCT/IB2019/060969, dated Jul. 14, 2020, 12 pages. [cited by applicant]
Junttila, T. et al., “Antitumor Efficacy of a Bispecic Antibody That Targets HER2 and Activates T Cells,” American Association for Cancer Research, vol. 74(19): 5561-5571 (2014). [cited by applicant]
Klein, C. et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” mAbs, vol. 4(6):653-663 (2012). [cited by applicant]
Labrijn et al., “Controlled fab-arm exchange for the generation of stable bispecific IgG1,” Nature Protocols, vol. 9(10): 2450-2463 (2014). [cited by applicant]
Labrijn et al., “Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange,” Proc Natl Acad Sci., vol. 110(13):5145-5150 (2013). [cited by applicant]
Labrijn, Aran F. et al., “Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3—CH3 Interaction Strength,” The Journal of Immunology, vol. 187, 9 pages (2011). [cited by applicant]
Labrijn, Aran F. et al., “Species-specific determinants in the immunoglobulin CH3 domain enable Fab-arm exchange by affecting the non-covalent CH3—CH3 interaction strength,” Keystone Symposium, Antibodies as Drugs Poste… [cited by applicant]
Labrijn, Aran F. et al., “Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo,” Nature Biotechnology, vol. 27(8):767-771 (2009). [cited by applicant]
Lewis, Kenneth B. et al., “Comparison of the ability of wild type and stabilized human IgG4 to undergo Fab arm exchange with endogenous IgG4 in vitro and in vivo,” Molecular Immunology, vol. 46:3488-3494 (2009). [cited by applicant]
Lindhofer, H. et al., “Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies,” J Immunol., vol. 155(1):219-225 (1995). [cited by applicant]
Lund, J. et al., “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” The Journal o… [cited by applicant]
Marvin, Jonathan S. et al., “Recombinant approaches to lgG-like bispecific antibodies,” Acta Pharmacologica Sinica, vol. 26(6):649-658 (2005). [cited by applicant]
Merchant, A. Margaret et al., “An efficient route to human bispecific IgG,” Nature Biotechnology, vol. 16:677-681 (1998). [cited by applicant]
Milstein C. et al., “Hybrid hybridomas and their use in immunohistochemistry,” Nature, vol. 305(5934):537-540 (1983). [cited by applicant]
Miosge, L. et al., “Comparison of predicted and actual consequences of missense mutations,” Proc Natl Acad Sci U S A., vol. 112(37):E5189-E5198 (2015). [cited by applicant]
Mori, Katsuhiro et al., “Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies,” Cytotechnology, vol. 55:109-114 (2007). [cited by applicant]
Nilson, B.H.K et al., “Purification of antibodies using protein L-binding framework structures in the light chain variable domain,” Journal of Immunological Methods, vol. 164(1): 33-40 (1993). [cited by applicant]
Doijevaar-De Heer, Pleuni G. et al., “Fc binding activity of IgG4 is a confounding factor in the measurement of IgG4 bispecificity,” Sanquin Spring Symposium, 1 page (2007). [cited by applicant]
U.S. Appl. No. 17/950,350, filed Sep. 22, 2022, Aran Frank Labrijn. [cited by applicant]
Kuo, T.T. et.al . “Neonatal Fc receptor and IgG-based therapeutics,” MABS, vol. 3(5): 422-430 (2011). [cited by applicant]
Cited By (2)
US 12,674,001 US 12,692,320